simvastatin has been researched along with Diabetic Angiopathies in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (12.82) | 18.2507 |
| 2000's | 24 (61.54) | 29.6817 |
| 2010's | 10 (25.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adler, GK; Bayomy, O; Di Carli, MF; Garg, R; Jerosch-Herold, M; Kotin, AR; Kwong, RY; Nijmeijer, S; Rao, AD; Reiber, B; Vaidya, A | 1 |
| Ni, Y; Sun, Z; Wang, Z; Xu, H; Zheng, L | 1 |
| Buranasupkajorn, P; Buse, JB; Doria, A; Gao, H; Gerstein, HC; Hastings, T; Kraft, P; Marcovina, SM; Mendonca, C; Morieri, ML; Motsinger-Reif, AA; Mychaleckyj, JC; Parè, G; Pigeyre, M; Rotroff, DM; Shah, HS; Sigal, RJ; Sjaarda, J; Wagner, MJ | 1 |
| Byington, RP; Crouse, JR; Elam, MB; Force, RW; Ginsberg, HN; Ismail-Beigi, F; Leiter, LA; Linz, PE; Lovato, LC; O'Connor, PJ; Papademetriou, V; Simmons, DL; Weiss, D | 1 |
| Golden, SH; Joseph, JJ | 1 |
| Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y | 1 |
| Chen, CY; Chen, JW; Chen, JY; Huang, PH; Lin, SJ; Shih, CC | 1 |
| Franssen, R; Kastelein, JJ; Stroes, ES; Vergeer, M | 1 |
| Ballantyne, CM; Cain, VA; Raichlen, JS | 1 |
| Chang, W; Hong, BK; Hwang, KC; Kim, M; Kwon, HM; Lee, BK; Lee, YH; Min, PK; Park, SJ; Rim, SJ; Yoon, SJ; Yoon, YW | 1 |
| Slany, J | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Vichayanrat, A | 1 |
| Ceriello, A | 1 |
| Kulkarni, M; Reaven, PD | 1 |
| Lawrence, I | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Ogrin, C; Perkelvald, A; Winer, N | 1 |
| Ganda, OP | 1 |
| Han, M; Li, JB; Liu, KZ; Lu, HL; Wen, JK | 1 |
| Beishuizen, ED; Huisman, MV; Jukema, JW; Meinders, AE; Tamsma, JT; van de Ree, MA; van der Vijver, JC | 1 |
| Schernthaner, G | 1 |
| Armitage, J; Briggs, A; Collins, R; Gray, A; Mihaylova, B; Parish, S | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Dollerup, J; Gormsen, LC; Mogensen, CE; Nellemann, B; Nielsen, S; Rasmussen, LM; Schmitz, O | 1 |
| Charbonnel, B; Dormandy, J; Erdmann, E; Massi-Benedetti, M; Wilcox, R | 1 |
| Böhm, F; Pernow, J; Rydén, L; Settergren, M | 1 |
| Haffner, SM | 1 |
| Faergeman, O; Kjekshus, J; Olsson, AG; Pedersen, TR; Pyŏrälä, K; Thorgeirsson, G | 1 |
| Mann, JI | 1 |
| Alexander, CM; Boccuzzi, SJ; Cook, JR; Herman, WH; Kjekshus, J; Musliner, TA; Pedersen, TR; Pyörälä, K | 1 |
| Cook, JR; Jönsson, B; Pedersen, TR | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
6 review(s) available for simvastatin and Diabetic Angiopathies
| Article | Year |
|---|---|
Type 2 diabetes and cardiovascular disease: what next?
Topics: Anticholesteremic Agents; Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Obesity; Risk Factors; Risk Reduction Behavior; Simvastatin; Sleep Wake Disorders; Socioeconomic Factors; Stress, Psychological | 2014 |
Combination statin-fibrate therapy: safety aspects.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Metabolic Syndrome; Practice Guidelines as Topic; Simvastatin | 2009 |
Nitrotyrosine: new findings as a marker of postprandial oxidative stress.
Topics: Animals; Biomarkers; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hyperglycemia; Hypertriglyceridemia; Hypolipidemic Agents; Oxidative Stress; Postprandial Period; Rats; Simvastatin; Tyrosine | 2002 |
The role of lipid management in diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Pyrroles; Simvastatin; Triglycerides | 2005 |
Is dyslipidaemia important if we control glycaemia?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Rhabdomyolysis; Risk Factors; Simvastatin | 2005 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
19 trial(s) available for simvastatin and Diabetic Angiopathies
| Article | Year |
|---|---|
Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus.
Topics: Adipose Tissue; Adiposity; Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Enalapril; Female; Humans; Male; Middle Aged; Pericardium; Plasminogen Activator Inhibitor 1; Risk Factors; Simvastatin | 2017 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fenofibrate; Genetic Association Studies; Genetic Markers; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Polymorphism, Single Nucleotide; Risk Assessment; Risk Factors; Simvastatin | 2018 |
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome | 2014 |
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides | 2013 |
Dose-expanded study in the reinforcement of efficacy of simvastatin.
Topics: Adult; Aged; Coronary Disease; Diabetic Angiopathies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Simvastatin | 2002 |
Heart protection study: LDL lowering therapy and cardiovascular outcomes in patients with low cholesterol levels or diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Treatment Outcome | 2002 |
Heart protection study: a focus on diabetic patients.
Topics: Coronary Disease; Diabetic Angiopathies; Double-Blind Method; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Placebos; Simvastatin; Stroke | 2004 |
[Effects of Astragalus and saponins of Panax notoginseng on MMP-9 in patients with type 2 diabetic macroangiopathy].
Topics: Aged; Astragalus propinquus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drugs, Chinese Herbal; Female; Ginsenosides; Humans; Hypolipidemic Agents; Lipids; Male; Matrix Metalloproteinase 9; Middle Aged; Panax; Phytotherapy; Plants, Medicinal; Simvastatin | 2004 |
The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease.
Topics: Blood Flow Velocity; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyridines; Simvastatin; Ultrasonography | 2005 |
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Coronary Disease; Cost-Benefit Analysis; Diabetic Angiopathies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Middle Aged; Quality-Adjusted Life Years; Risk Factors; Simvastatin | 2006 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
Topics: Albuminuria; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteoprotegerin; Simvastatin | 2007 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Brachial Artery; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation Mediators; Lipids; Male; Middle Aged; Plethysmography; Regional Blood Flow; Simvastatin; Vasodilation | 2008 |
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Lovastatin; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Placebos; Prognosis; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Time Factors; Triglycerides | 1997 |
Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Glucose Intolerance; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Scandinavian and Nordic Countries; Simvastatin; Survival Rate | 1999 |
The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
Topics: Adult; Aged; Coronary Disease; Cost-Benefit Analysis; Diabetic Angiopathies; Drug Costs; Female; Health Care Costs; Hospitalization; Humans; Hypolipidemic Agents; Male; Middle Aged; Probability; Prognosis; Prospective Studies; Simvastatin; Survival Analysis | 1999 |
15 other study(ies) available for simvastatin and Diabetic Angiopathies
| Article | Year |
|---|---|
GATA4 protects against hyperglycemia‑induced endothelial dysfunction by regulating NOX4 transcription.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Enzyme Induction; GATA4 Transcription Factor; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Hyperglycemia; Male; Mice, Inbred C57BL; NADPH Oxidase 4; Nitric Oxide; Simvastatin | 2018 |
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Drug Therapy, Combination; Female; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; MicroRNAs; Muscle, Smooth, Vascular; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Renal Artery; rho-Associated Kinases; Simvastatin; Vasculitis | 2015 |
Simvastatin pretreatment enhances ischemia-induced neovascularization and blood flow recovery in streptozotocin-treated mice.
Topics: Animals; Blood Flow Velocity; Collateral Circulation; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelial Progenitor Cells; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Mice; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Phosphorylation; Recovery of Function; Regional Blood Flow; Simvastatin; Streptozocin; Time Factors; Vascular Endothelial Growth Factor A; Vasodilation | 2016 |
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy.
Topics: Animals; Aorta; Cell Proliferation; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glycation End Products, Advanced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocytes, Smooth Muscle; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Simvastatin; Transcription Factor RelA | 2009 |
[Achievement of blood lipid target levels with Ezetimibe/Simvastatin in patients with atherosclerosis and/or diabetes mellitus--an Austrian observational study].
Topics: Age Factors; Aged; Anticholesteremic Agents; Austria; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Simvastatin; Triglycerides | 2009 |
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2010 |
Continuing education.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Simvastatin; Thiazoles; Thiazolidinediones | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
[Preventing infarct by lowering LDL. Is 100 the upper limit for every diabetic patient?].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Diabetic Angiopathies; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Myocardial Infarction; Reference Values; Risk Factors; Simvastatin; Survival Rate | 2003 |
A cholesterol drug protects some people with diabetes.
Topics: Anticholesteremic Agents; Diabetic Angiopathies; Humans; Myocardial Infarction; Simvastatin; Stroke | 2003 |
Wider role seen for "remarkable" statins. Study suggests that benefits extend even to those with "normal" cholesterol levels.
Topics: Anticholesteremic Agents; Diabetic Angiopathies; Female; Humans; Male; Myocardial Infarction; Simvastatin; Stroke; Treatment Refusal | 2002 |
The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Diabetic Angiopathies; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Triglycerides | 1997 |
The role of nutritional modifications in the prevention of macrovascular complications of diabetes.
Topics: Antioxidants; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diet Therapy; Energy Intake; Energy Metabolism; Humans; Lovastatin; Minerals; Obesity; Simvastatin; Vitamins | 1997 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |